BACKGROUND: Recessive dystrophic epidermolysis bullosa is an incurable, often fatal mucocutaneous blistering disease caused by mutations in COL7A1, the gene encoding type VII collagen (C7). On the basis of preclinical data showing biochemical correction and prolonged survival in col7 −/− mice, we hypothesized that allogeneic marrow contains stem cells capable of ameliorating the manifestations of recessive dystrophic epidermolysis bullosa in humans. METHODS: Between October 2007 and August 2009, we treated seven children who had recessive dystrophic epidermolysis bullosa with immunomyeloablative chemotherapy and allogeneic stem-cell transplantation. We assessed C7 expression by means of immunofluorescence staining and used transmission electron microscopy to visualize anchoring fibrils. We measured chimerism by means of competitive polymerase-chain-reaction assay, and documented blister formation and wound healing with the use of digital photography. RESULTS: One patient died of cardiomyopathy before transplantation. Of the remaining six patients, one had severe regimen-related cutaneous toxicity, with all having improved wound healing and a reduction in blister formation between 30 and 130 days after transplantation. We observed increased C7 deposition at the dermal-epidermal junction in five of the six recipients, albeit without normalization of anchoring fibrils. Five recipients were alive 130 to 799 days after transplantation; one died at 183 days as a consequence of graft rejection and infection. The six recipients had substantial proportions of donor cells in the skin, and none had detectable anti-C7 antibodies. CONCLUSIONS: Increased C7 deposition and a sustained presence of donor cells were found in the skin of children with recessive dystrophic epidermolysis bullosa after allogeneic bone marrow transplantation. Further studies are needed to assess the long-term risks and benefits of such therapy in patients with this disorder. (Funded by the National Institutes of Health; ClinicalTrials.gov number, NCT00478244.)
BACKGROUND:Recessive dystrophic epidermolysis bullosa is an incurable, often fatal mucocutaneous blistering disease caused by mutations in COL7A1, the gene encoding type VII collagen (C7). On the basis of preclinical data showing biochemical correction and prolonged survival in col7 −/− mice, we hypothesized that allogeneic marrow contains stem cells capable of ameliorating the manifestations of recessive dystrophic epidermolysis bullosa in humans. METHODS: Between October 2007 and August 2009, we treated seven children who had recessive dystrophic epidermolysis bullosa with immunomyeloablative chemotherapy and allogeneic stem-cell transplantation. We assessed C7 expression by means of immunofluorescence staining and used transmission electron microscopy to visualize anchoring fibrils. We measured chimerism by means of competitive polymerase-chain-reaction assay, and documented blister formation and wound healing with the use of digital photography. RESULTS: One patient died of cardiomyopathy before transplantation. Of the remaining six patients, one had severe regimen-related cutaneous toxicity, with all having improved wound healing and a reduction in blister formation between 30 and 130 days after transplantation. We observed increased C7 deposition at the dermal-epidermal junction in five of the six recipients, albeit without normalization of anchoring fibrils. Five recipients were alive 130 to 799 days after transplantation; one died at 183 days as a consequence of graft rejection and infection. The six recipients had substantial proportions of donor cells in the skin, and none had detectable anti-C7 antibodies. CONCLUSIONS: Increased C7 deposition and a sustained presence of donor cells were found in the skin of children with recessive dystrophic epidermolysis bullosa after allogeneic bone marrow transplantation. Further studies are needed to assess the long-term risks and benefits of such therapy in patients with this disorder. (Funded by the National Institutes of Health; ClinicalTrials.gov number, NCT00478244.)
Authors: Mei Chen; Noriyuki Kasahara; Douglas R Keene; Lawrence Chan; Warren K Hoeffler; Deborah Finlay; Maria Barcova; Paula M Cannon; Constance Mazurek; David T Woodley Journal: Nat Genet Date: 2002-11-11 Impact factor: 38.330
Authors: Jakub Tolar; Akemi Ishida-Yamamoto; Megan Riddle; Ron T McElmurry; Mark Osborn; Lily Xia; Troy Lund; Catherine Slattery; Jouni Uitto; Angela M Christiano; John E Wagner; Bruce R Blazar Journal: Blood Date: 2008-10-27 Impact factor: 22.113
Authors: Susana Ortiz-Urda; Bhaskar Thyagarajan; Douglas R Keene; Qun Lin; Min Fang; Michele P Calos; Paul A Khavari Journal: Nat Med Date: 2002-09-16 Impact factor: 53.440
Authors: Susana Ortiz-Urda; Qun Lin; Cheryl L Green; Douglas R Keene; M Peter Marinkovich; Paul A Khavari Journal: J Clin Invest Date: 2003-01 Impact factor: 14.808
Authors: Tracy Wong; Luke Gammon; Lu Liu; Jemima E Mellerio; Patricia J C Dopping-Hepenstal; John Pacy; George Elia; Rosemary Jeffery; Irene M Leigh; Harshad Navsaria; John A McGrath Journal: J Invest Dermatol Date: 2008-04-03 Impact factor: 8.551
Authors: M Endo; P W Zoltick; A Radu; Q Jiang; J Qiujie; C Matsui; P M Marinkovich; J McGrath; K Tamai; J Uitto; A W Flake Journal: Gene Ther Date: 2011-09-22 Impact factor: 5.250
Authors: Qing Lin; Russell N Wesson; Hiromichi Maeda; Yongchun Wang; Zhu Cui; Jun O Liu; Andrew M Cameron; Bin Gao; Robert A Montgomery; George M Williams; Zhaoli Sun Journal: J Invest Dermatol Date: 2014-03-28 Impact factor: 8.551
Authors: Jon Cogan; Jacqueline Weinstein; Xinyi Wang; Yingping Hou; Sabrina Martin; Andrew P South; David T Woodley; Mei Chen Journal: Mol Ther Date: 2014-07-23 Impact factor: 11.454
Authors: Gabriela Petrof; Su M Lwin; Magdalena Martinez-Queipo; Alya Abdul-Wahab; Simon Tso; Jemima E Mellerio; Ineke Slaper-Cortenbach; Jaap J Boelens; Jakub Tolar; Paul Veys; Mercy Ofuya; Janet L Peacock; Anna E Martinez; John A McGrath Journal: J Invest Dermatol Date: 2015-04-23 Impact factor: 8.551